Elizabeth Yeu Lin - 25 Jan 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
4
Filing time
30 Jan 2024, 16:31:48 UTC
Previous filing
22 Sep 2023
Next filing
14 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +10,000 $0.000000 10,000 25 Jan 2024 Common Stock 10,000 $26.25 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Option granted in connection with certain consulting services being provided by the Reporting Person. The option will vest in full on January 30, 2025, subject to the Reporting Person's continuous service through such date.